TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating) shares were down 9.8% during mid-day trading on Friday . The stock traded as low as $0.11 and last traded at $0.11. Approximately 1,500 shares traded hands during mid-day trading, a decline of 97% from the average daily volume of 58,702 shares. The stock had previously closed at $0.13.
TC Biopharm Stock Down 9.8 %
The firm’s fifty day moving average is $0.14 and its 200-day moving average is $0.15.
Institutional Trading of TC Biopharm
An institutional investor recently bought a new position in TC Biopharm stock. Nantahala Capital Management LLC bought a new position in shares of TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 235,294 shares of the company’s stock, valued at approximately $117,000.
TC Biopharm Company Profile
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types.
- Get a free copy of the StockNews.com research report on TC Biopharm (TCBPW)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for TC Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TC Biopharm and related companies with MarketBeat.com's FREE daily email newsletter.